Onesource Specialty Pharma Share Price
1544.20-31.50 (-2.00%)
-18.68% past 1 Year
OneSource Specialty Pharma is evolved into an integrated, multimodal specialty pharmaceutical CDMO. The company specialises in offering end-to-end solutions across biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatin
Corporate filings & documents
Announcements
Intimation of the investor presentation
1 day agoIntimation of the investor presentation
1 day agoNewspaper advertisement confirming the dispatch of the notice convening the 19th AGM of the Company and Remote e-voting
2 days agoNewspaper advertisement confirming the dispatch of the notice convening the 19th AGM of the Company and Remote e-voting
2 days agoIntimation of the Notice of the 19th AGM (2nd AGM after listing) to be held on September 23 2026 at 5:00 pm through Video Conferencing or other Audio Visual Means
3 days agoIntimation of the Notice of the 19th AGM (2nd AGM after listing) to be held on September 23 2026 at 5:00 pm through Video Conferencing or other Audio Visual Means
3 days agoBusiness Responsibility and Sustainability Report for the FY 2026
3 days agoBusiness Responsibility and Sustainability Report for the FY 2026
3 days agoAnnual Report for FY 2025-26
3 days agoAnnual Report for FY 2025-26
3 days agoAnnual Report for FY 2025-26
3 days agoAnnual Report for FY 2025-26
3 days agoIntimation of Investors called scheduled on September 03 2026 at 10:00 AM.
3 days agoIntimation of Investors called scheduled on September 03 2026 at 10:00 AM.
3 days agoNewspaper advertisement regarding the 19th Annual General Meeting of the Company
5 days agoNewspaper advertisement regarding the 19th Annual General Meeting of the Company
5 days agoIntimation of Credit Rating issued by India Ratings and Research Private Limited vide press release dated August 17 2026
2 weeks agoIntimation of Credit Rating issued by India Ratings and Research Private Limited vide press release dated August 17 2026
2 weeks agoIntimation of Transcript of Earnings call dated July 25 2026
1 month agoIntimation of Transcript of Earnings call dated July 25 2026
1 month agoChanges in Senior Management Personnel (SMP) of the Company - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
1 month agoChanges in Senior Management Personnel (SMP) of the Company - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
1 month agoIntimation about publication of newspaper advertisement- Extract of unaudited Standalone and Consolidated financial results for the quarter ended June 30 2026.
1 month agoIntimation about publication of newspaper advertisement- Extract of unaudited Standalone and Consolidated financial results for the quarter ended June 30 2026.
1 month agoIntimation of Audio Recording of Earnings call pertaining to the Unaudited Financial Results for the quarter ended June 30 2026
1 month agoIntimation of Audio Recording of Earnings call pertaining to the Unaudited Financial Results for the quarter ended June 30 2026
1 month agoIntimation of allotment of 2 900 ESOPs of Re.1 each under ONESOURCE ESOP 2021
1 month agoIntimation of allotment of 2 900 ESOPs of Re.1 each under ONESOURCE ESOP 2021
1 month agoOneSource announces strong Q1FY27 results Revenue up 37% YoY and EBITDA up 39% YoY
1 month agoOneSource announces strong Q1FY27 results Revenue up 37% YoY and EBITDA up 39% YoY
1 month agoChanges in the Senior Managament Personnel of the Company-Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
1 month agoChanges in the Senior Managament Personnel of the Company-Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
1 month agoOutcome of the Board meeting dated July 24 2026 for the approval of the unaudited financial results (Standalone and Consolidated) for the quarter ended June 30 2026.
1 month agoOutcome of the Board meeting dated July 24 2026 for the approval of the unaudited financial results (Standalone and Consolidated) for the quarter ended June 30 2026.
1 month agoIntimation of Earnings Call to be held on July 25 2026.
1 month agoIntimation of Earnings Call to be held on July 25 2026.
1 month agoOnesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 inter alia to consider and approve Unaudited financial results (Standalone and Consolidated) for the quarter ended June 30 2026.
1 month agoOnesource Specialty Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2026 inter alia to consider and approve Unaudited financial results (Standalone and Consolidated) for the quarter ended June 30 2026.
1 month agoOneSource Specialty Pharma and Formycon AG announce Strategic Manufacturing Partnership for Biosimilars
1 month agoOneSource Specialty Pharma and Formycon AG announce Strategic Manufacturing Partnership for Biosimilars
1 month agoWe refer to the intimation made earlier today by Dr. Reddys Laboratories (DRL) regarding delay in commercial supplies of Semaglutide. Refer intimation attached.
1 month agoWe refer to the intimation made earlier today by Dr. Reddys Laboratories (DRL) regarding delay in commercial supplies of Semaglutide. Refer intimation attached.
1 month agoAllotment of 24 190 equity shares of Re. 1/- under ONESOURCE ESOP 2021 on July 08 2026.
1 month agoAllotment of 24 190 equity shares of Re. 1/- under ONESOURCE ESOP 2021 on July 08 2026.
1 month agoWe wish to inform that a routine current Good Manufacturing (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility (SPD) of OneSource Specialty Pharma Limited from June 22 2026 to June 30 2026.The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame.
2 months agoWe wish to inform that a routine current Good Manufacturing (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Sterile Product Division facility (SPD) of OneSource Specialty Pharma Limited from June 22 2026 to June 30 2026.The inspection has concluded with one observation. The Company will respond to the observation comprehensively to FDA within the stipulated time frame.
2 months agoIntimation of closure of Trading window for declaration of unaudited financial results for the quarter ended June 30 2026.
2 months agoIntimation of closure of Trading window for declaration of unaudited financial results for the quarter ended June 30 2026.
2 months agoIntimation of Transcript of Earnings call dated May 13 2026
3 months agoIntimation of Transcript of Earnings call dated May 13 2026
3 months agoAnnual reports
Concalls & investor presentations
Jul 2026
ConcallPresentation
Jul 2026
ConcallPresentation
May 2026
Jan 2026
ConcallPresentation
Jan 2026
ConcallPresentation
Aug 2025
ConcallPresentation
May 2025
ConcallPresentation
May 2025
ConcallPresentation
Jan 2025
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Unit No. 902, Cyber One Plot No - 4 & 6 Sector 30 A, Vashi Navi Mumbai Maharashtra PIN: 400703 Tel No: 022 2789 2924 Fax No: 022 2789 2942 Email: [email protected] Internet: www.onesourcecdmo.com
Registrars
II Floor , Kences Towers,No 1 Ramakrishna Street,North Usman Road, T Nagar,Chennai II Floor , Kences Towers No 1 Ramakrishna Street North Usman Road, T Nagar PIN: Tel No: 044-28140801 Fax No: 044-28142479 Email: [email protected] Internet: [email protected]
Management
A Trisha, Company Secretary & Compliance Officer
Arun Kumar, Chairman
Debarati Sen, Non Executive Independent Director
Claudio Albrecht, Non Executive Independent Director
Rashmi Barbhaiya, Non Executive Independent Director
Colin Michael Bond, Non Executive Independent Director
Vijay Karwal, Non Executive Independent Director
Bharat D Shah, Non Executive Director
Neeraj Sharma, Managing Director & Chief Executive Officer
Details
BSE 544292
NSE ONESOURCE
ISIN INE013P01021